Advantages and disadvantages of biodegradable platforms in drug eluting stents

doi:10.4330/wjc.v3.i3.84

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4907)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

400

HTML

4132

Figures (1-3)

172

Tables (1-4)

203

Sum=4907

Mar 26, 2011 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Mar 26, 2011; 3(3): 84-92
Published online Mar 26, 2011. doi: 10.4330/wjc.v3.i3.84

Full Size Figure Download Figure

Figure 2 EUCATAX randomized trial design. Modified form Rodriguez et al[39]. Pts: Patients; PCI: Percutaneous coronary interventions; PES: Paclitaxel eluting stent; BMS: Bare-metal stent.

Citation: Rodriguez-Granillo A, Rubilar B, Rodriguez-Granillo G, Rodriguez AE. Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol 2011; 3(3): 84-92
URL: https://www.wjgnet.com/1949-8462/full/v3/i3/84.htm
DOI: https://dx.doi.org/10.4330/wjc.v3.i3.84